相关实验视频

Updated: Jun 1, 2025

Tuning Degradation to Achieve Specific and Efficient Protein Depletion

Tuning Degradation to Achieve Specific and Efficient Protein Depletion

Published on: July 20, 2019

使用基于PROTAC的方法降解突变IDH1会损害STAT3激活

Hashnu Dutta¹, Nishant Jain¹

¹Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, 500007, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.

Archives of biochemistry and biophysics

|January 19, 2025

概括

通过PROteolysis TTargeting Chimera (PROTAC) 疗法降解突变异酸盐脱酶1 (IDH1) 不会激活STAT3,与目前的抑制剂不同. 这表明PROTAC是克服IDH1突变质瘤耐药性的有希望的策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

同位酸脱酶1 (IDH1) 中的异基突变在II级和III级脑瘤中很普遍.
目前的IDH1抑制剂可以矛盾地激活STAT3,从而导致药物耐药性.
蛋白质溶解向基因组 (PROTAC) 技术为降解向蛋白质提供了一种替代方法.

研究的目的:

调查使用基于PROTAC的方法降解突变IDH1是否会导致STAT3激活.
探索PROTACs作为IDH1-突变结质瘤的替代治疗策略.

主要方法:

利用dTAG系统将FKBP12^F36V与突变的IDH1蛋白进行融合.
使用FKBP12^F36V特定的PROTAC,dTAG-13,诱导突变IDH1-FKBP12^{F36V的降解.}
在用dTAG-13治疗的细胞中评估了STAT3激活 (pSTAT3-Y705).

主要成果:

FKBP12^F36V-HA与突变IDH1的融合并没有改变其表达,活性或定位.
在剂量和时间上,dTAG-13有效降解突变IDH1-FKBP12^F36V-HA.
突变IDH1-FKBP12^F36V-HA的降解没有导致STAT3激活 (pSTAT3-Y705).

结论:

通过PROTACs降解突变的IDH1有效地损害了STAT3的激活,与传统的抑制剂不同.
基于PROTAC的策略代表了开发针对IDH1-突变质瘤的治疗方法的可行替代方案.
这种方法可以克服与当前的IDH1抑制剂疗法相关的耐药性.

关键词:

FKBP12 (((F36V) 的意思是突变的IDH1是一个突变的IDH1.这就是PROTAC.在STAT3中,我们可以使用STAT3.在Ubiquitination中使用.在 dTAG-13 中.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...